A human antibody to the CD4 binding site of gp120 capable of highly potent but sporadic cross clade neutralization of primary HIV-1.
about
Vaccine-Elicited Tier 2 HIV-1 Neutralizing Antibodies Bind to Quaternary Epitopes Involving Glycan-Deficient Patches Proximal to the CD4 Binding SiteThe Neonatal Fc receptor (FcRn) enhances human immunodeficiency virus type 1 (HIV-1) transcytosis across epithelial cellsRecent Insights into the HIV/AIDS Pandemic.Receptor binding domain based HIV vaccines.A High Throughput Protein Microarray Approach to Classify HIV Monoclonal Antibodies and Variant Antigens.Functional and Structural Characterization of Human V3-Specific Monoclonal Antibody 2424 with Neutralizing Activity against HIV-1 JRFLHIV-1-Specific Antibody Response and Function after DNA Prime and Recombinant Adenovirus 5 Boost HIV Vaccine in HIV-Infected Subjects.Glycan modulation and sulfoengineering of anti-HIV-1 monoclonal antibody PG9 in plants.HIV-specific CD4-induced Antibodies Mediate Broad and Potent Antibody-dependent Cellular Cytotoxicity Activity and Are Commonly Detected in Plasma From HIV-infected humansStructure-Based Design of a Small Molecule CD4-Antagonist with Broad Spectrum Anti-HIV-1 Activity.HIV-1 specific antibody titers and neutralization among chronically infected patients on long-term suppressive antiretroviral therapy (ART): a cross-sectional study.Introduction of germline residues improves the stability of anti-HIV mAb 2G12-IgMHuman immunodeficiency virus type-1 (HIV-1) evades antibody-dependent phagocytosis.Modeling cumulative overall prevention efficacy for the VRC01 phase 2b efficacy trials.
P2860
Q27319450-C9D270D7-E389-488F-B13A-23405AFEB45FQ28302792-CC56DECA-B48B-4514-81BD-C5AA30D98234Q30235024-84A1ABD9-5E95-4CA8-8DDA-E6CD2C972D5FQ35033862-59CE0391-ACD0-4985-875C-F1E810E35D81Q35566508-9A8349BD-D98E-4822-9E3A-C71E55C6218AQ35913910-1C13617E-9D16-4E39-819F-05A0DAAA3756Q36097352-EF40ABD5-FEC0-4FD9-8095-E9D7BBDFDB81Q36179265-81F1B8E7-06C2-4580-BBE8-29137018782FQ36252656-4A9A7463-91C2-4F5A-B884-06B2286CA22AQ36364955-4A60A566-8B1C-4DD0-A859-8AF5BACFCFCDQ37484124-1546C46D-B7F1-4F98-A04D-FB03B23E018DQ41273804-2C9E63EB-27A6-4818-BE95-AF9E8042222DQ47215816-322544A8-D759-4C03-8FAE-0A85FEE62DC0Q54230395-908B2181-4520-423F-BD74-6BA6B174EB48
P2860
A human antibody to the CD4 binding site of gp120 capable of highly potent but sporadic cross clade neutralization of primary HIV-1.
description
2013 nî lūn-bûn
@nan
2013 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
A human antibody to the CD4 bi ...... utralization of primary HIV-1.
@ast
A human antibody to the CD4 bi ...... utralization of primary HIV-1.
@en
type
label
A human antibody to the CD4 bi ...... utralization of primary HIV-1.
@ast
A human antibody to the CD4 bi ...... utralization of primary HIV-1.
@en
prefLabel
A human antibody to the CD4 bi ...... utralization of primary HIV-1.
@ast
A human antibody to the CD4 bi ...... utralization of primary HIV-1.
@en
P2093
P2860
P1433
P1476
A human antibody to the CD4 bi ...... utralization of primary HIV-1.
@en
P2093
Donald N Forthal
Heribert Quendler
James M Binley
Kristin M Narayan
Michael B Zwick
Robert G Whalen
Tommy Tong
P2860
P304
P356
10.1371/JOURNAL.PONE.0072054
P407
P577
2013-08-26T00:00:00Z